According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.